News & Insights
Analysis and perspectives on pharmaceutical pricing, market access, IRP, MFN policy, and AI-powered pricing tools.
Stay up to date with the latest developments in pharmaceutical pricing policy, including GENEROUS, MFN, and International Reference Pricing.
Sympatics at the World EPA Congress 2026 – Amsterdam, 3–4 March
The Sympatics team will be at the World Evidence, Pricing and Access (EPA) Congress in Amsterdam on 3–4 March 2026, Europe’s largest congress for market…
MFN and the Shift of Risk for Ex-US Markets
Global Strategy Rosemarie Delaney PhD•February 2026•6 min read MFN and the Shift of Risk for Ex-US Markets Although MFN policies are designed for the US,…
Redefining Ex-US Success in an MFN World
Global Strategy Rosemarie Delaney PhD•February 2026•5 min read Redefining Ex-US Success in an MFN World In an MFN-driven pricing environment, ex-US success is no longer…
The End of Two Silos: Why Pharmaceutical Pricing Is Now a Single Global Challenge
Pricing Strategy The End of Two Silos: Why Pharmaceutical Pricing Is Now a Single Global Challenge Rosemarie Delaney PhD • February 2026 • 8 min…
The Fine Print: Three Details in GLOBE & GUARD That Could Reshape Your MFN Strategy
Deep Dive Beyond the headlines, the GLOBE and GUARD proposed rules contain regulatory nuances that most coverage has overlooked. These details aren’t bugs—they’re features with…
Decoding GLOBE & GUARD: Medicare’s New MFN Models
Policy Analysis GLOBE & GUARD: MFN Pricing Comes to Medicare January 2026 • 10 min read In December 2025, the CMS Innovation Center released proposed…
GENEROUS: Medicaid’s MFN test—what it is, why it matters now
Policy Analysis GENEROUS: MFN Comes to Medicaid How CMS is turning international reference pricing into guaranteed net prices for state drug programs January 2026 •…
Stay Updated
Get in touch to learn more about our AI-powered pharmaceutical pricing tools and stay informed on the latest policy developments.